Tag Archives: NASDAQ:EPZM

Epizyme (EPZM) Receives a Buy from Cowen & Co.

In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Epizyme (EPZM – Research Report), with a price target of $18.00. The company’s shares closed last Monday at $11.56. According to TipRanks.com, Werber is

A Director at Epizyme (NASDAQ: EPZM) is Selling Shares

Today, a Director at Epizyme (EPZM – Research Report), David Mott, sold shares of EPZM for $1.37M. This is Mott’s first Sell trade following 5 Buy transactions. Following David Mott’s last EPZM Sell transaction on October 05, 2018, the stock

Cowen & Co. Maintains a Buy Rating on Epizyme (EPZM)

In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Epizyme (EPZM – Research Report), with a price target of $18. The company’s shares closed yesterday at $11.46. According to TipRanks.com, Werber is a

Oppenheimer Initiates a Buy Rating on Epizyme (EPZM)

Oppenheimer analyst Leland Gershell initiated coverage with a Buy rating on Epizyme (EPZM – Research Report) today and set a price target of $18. The company’s shares closed yesterday at $13.76. Gershell commented: “We are assuming coverage of EPZM with

Cowen & Co. Keeps a Buy Rating on Epizyme (EPZM)

In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Epizyme (EPZM – Research Report), with a price target of $18. The company’s shares opened today at $12.76. According to TipRanks.com, Werber is ranked

Epizyme (EPZM) Receives a Buy from Oppenheimer

Oppenheimer analyst Leland Gershell reiterated a Buy rating on Epizyme (EPZM – Research Report) today and set a price target of $27. The company’s shares opened today at $7.94. Gershell observed: “Beyond providing increased visibility on tazemetostat’s path to approval